Von Willebrand Disease, Type 1 Clinical Trial
Official title:
Assessing the Bleeding Severity in Type I Von Willebrand Patients Using the International Society on Thrombosis and Hemostasis Bleeding Assessment Tool ( ISTH-BAT) Questionnaire
Verified date | September 2019 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Applying the ISTH-BAT questionnaire on Egyptian patients with type I VWD aiming to correlate the BS with the laboratory findings
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | March 1, 2021 |
Est. primary completion date | December 1, 2020 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: - type 1 vWD patients - healthy subjects with no known problem with bleeding or bruising were also recruited Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the International Society on Thrombosis and Hemostasis-Bleeding Assessment Tool (ISTH-BAT) | Questionnaire minimum score ranges from 0 to 10 whereas maximum score ranges from 20 to 30 | one year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06064851 -
Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Von Willebrand Disease Patients
|
N/A |